Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint ...

An announcement from Perspective Therapeutics ( ($CATX) ) is now available. On December 1, 2025, Perspective Therapeutics updated its corporate ...

IBI3003 is a novel trispecific antibody targeting GPRC5D, BCMA and CD3 simultaneously. Its dual-targeting design against BCMA and GPRC5 aims to overcome single antigen escape in multiple myeloma (MM).

Akeso, Inc. (9926.HK) (Akeso or the Company) announced the presentation of a Phase II clinical study that included a ...

Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant ...

Gov Hyacinth Iormem Alia of Benue State has said that he is determined to fix the broken Benue, some indigenes believed him ...

Rusfertide was generally well-tolerated through 52 Weeks of treatment. The most common treatment-emergent adverse events (AE) in rusfertide-treated patients were injection site reactions (47.4%), ...

The Prada Group announced Tuesday that it has officially purchased Milan fashion rival Versace in a 1.25 billion euro (nearly ...

MPACT’s VivoCity reported positive rental reversion of 14.1% in 2QFY2026 ended Sept 30. UOBKH thinks MPACT will be acquired ...

The U. of Tulsa was a commuter campus that tried — and tried again — to become a regional powerhouse. Now it’s drowning in ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY ® (exagamglogene autotemcel) in people ages 5 years and ...

The slow pace of the federal antitrust suit lodged against NASCAR continued Monday at the start of the second week of the ...